SK Chemicals
SK Chemicals

SK Chemicals is a member of one of the leading multi-profile holdings in South Korea, SK Group. SK Chemicals specializes in the development and production of biotechnological and pharmaceutical drugs – vaccines, blood products and pharmaceutical products. The company has developed various vaccines such as tri/quadrivalent cell-culture based influenza vaccines, varicella zoster vaccine, pneumococcal vaccine, and so on. Partners of SK Chemicals include leading international business and public organizations.

Valneva
Valneva

Valneva is a fully integrated, commercial stage biotech company focused on developing innovative life-saving vaccines.

 

The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability.

 

Valneva’s portfolio includes two commercial vaccines for travellers, while the Company has proprietary vaccines in development including a unique vaccine against Lyme disease. A variety of partnerships with leading pharmaceutical companies complement the Company’s value proposition and include vaccines being developed using Valneva’s innovative and validated technology platforms.

 

Valneva is incorporated in Lyon, France, listed on Euronext-Paris and the Vienna stock exchange and tradable on Deutsche Börse’s electronic platform Xetra®. The Company has operations in France, Austria, Scotland, UK, Sweden, US and Canada with approximately 400 employees.

Imaxio
Imaxio

Founded in 2000, IMAXIO is a biotech company specializing in the field of vaccinology.

 

Owing to his significant scientific and commercial expertise, IMAXIO is active in all stages of the life cycle of vaccines, from development through to market release. IMAXIO is specialised in the prevention of human leptospirosis.

 

IMAXIO has an international business presence, particularly in Asia where the company maintains a partnership for the distribution of the leptospirosis vaccine, and plans to extend its activities into new markets, most notably in Europe via a number of distribution partnerships. For the French market, IMAXIO is open to the establishment of agreements for distribution and product purchasing licenses, whether in the fields of workplace health and safety or travel-related illness.

SK Chemicals is a member of one of the leading multi-profile holdings in South Korea, SK Group. SK Chemicals specializes in the development and production of biotechnological and pharmaceutical drugs – vaccines, blood products and pharmaceutical products. The company has developed various vaccines such as tri/quadrivalent cell-culture based influenza vaccines, varicella zoster vaccine, pneumococcal vaccine, and so on. Partners of SK Chemicals include leading international business and public organizations.

Valneva is a fully integrated, commercial stage biotech company focused on developing innovative life-saving vaccines.

 

The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability.

 

Valneva’s portfolio includes two commercial vaccines for travellers, while the Company has proprietary vaccines in development including a unique vaccine against Lyme disease. A variety of partnerships with leading pharmaceutical companies complement the Company’s value proposition and include vaccines being developed using Valneva’s innovative and validated technology platforms.

 

Valneva is incorporated in Lyon, France, listed on Euronext-Paris and the Vienna stock exchange and tradable on Deutsche Börse’s electronic platform Xetra®. The Company has operations in France, Austria, Scotland, UK, Sweden, US and Canada with approximately 400 employees.

Founded in 2000, IMAXIO is a biotech company specializing in the field of vaccinology.

 

Owing to his significant scientific and commercial expertise, IMAXIO is active in all stages of the life cycle of vaccines, from development through to market release. IMAXIO is specialised in the prevention of human leptospirosis.

 

IMAXIO has an international business presence, particularly in Asia where the company maintains a partnership for the distribution of the leptospirosis vaccine, and plans to extend its activities into new markets, most notably in Europe via a number of distribution partnerships. For the French market, IMAXIO is open to the establishment of agreements for distribution and product purchasing licenses, whether in the fields of workplace health and safety or travel-related illness.